Table 2.

Clinical and biological predictors of early platelet drop

VariableRelative platelet drop
≤25% (n = 632)>25% (n = 175)PMultivariate
n or median% or IQRn or median% or IQROR95% CIP
Sex     .4    
 Male 394 62.3% 103 58.9%     
 Female 238 37.7% 72 41.1%     
Age, y 73 67-79 73 66-79 .5    
WHO classification at diagnosis     .015    
 RA 113 17.9% 28 16.0%  1   
 RARS 122 19.3% 17 9.7%  0.7 0.3-1.3 .2 
 RCMD 230 36.4% 79 45.1%  1.3 0.8-2.1 .4 
 RCMD-RS 39 6.1% 12 6.9%  1.2 0.5-2.5 .7 
 5q− syndrome 34 5.4% 15 8.6%  1.0 0.4-.26 .9 
 RAEB-1 74 11.7% 20 11.4%  0.7 0.4-1.5 .4 
 RAEB-2 0 0.0% 1 0.6%     
 MDS-U 20 3.2% 3 1.7%  0.6 0.2-2.4 .45 
IPSS at inclusion     <10−4    
 Low 332 55.5% 61 36.7%     
 Intermediate-1 266 44.5% 105 63.3%     
BM blasts, %     .1    
 ≤2 362 60.7% 85 51.8%     
 >2 to <5 162 27.2% 51 31.1%     
 5-10 69 11.6% 28 17.1%     
 >10 3 0.5% 0 0.0%     
Peripheral blasts, %     .4    
 <1 477 75.5% 127 72.6%     
 ≥1 155 24.5% 48 27.4%     
No. of cytopenias     <10−4    
 0 132 20.9% 19 10.9%  1   
 1 332 52.5% 84 48.0%  1.3 0.7-2.4 .3 
 2 126 19.9% 46 26.2%  1.7 0.9-3.2 .1 
 3 42 6.7% 26 14.9%  2.4 1.1-5.2 .03 
IPSS-R cytogenetic risk     .5    
 Very good 64 11.2% 20 12.5%     
 Good 431 75.6% 112 70.0%     
 Intermediate 65 11.4% 24 15.0%     
 Poor/very poor 10 1.8% 4 2.5%     
IPSS-R at inclusion     .024    
 Very low 151 27.8% 29 19.7%     
 Low 238 43.7% 59 40.1%     
 Intermediate 118 21.7% 49 33.4%     
 High 32 5.9% 10 6.8%     
 Very high 5 0.9% 0 0%     
Hb level, g/dL 10.2 9.3-11.4 9.5 8.5-10.7 <10−4 0.9 0.8-1.1 .2 
RBC-TD at inclusion     <10−4   .02 
 No 499 79.0% 102 58.3%  1   
 Yes 133 21.0% 73 41.7%  1.7 1.1-2.6  
Platelets, ×109/L 184 108-277 155 89-261 .6    
Neutrophils, ×109/L 2.4 1.5-3.9 2.1 1.2-3.8 .8    
Treatment before landmark     <10−4    
 ESA with or without G-CSF 205 32.4% 72 41.1%     
 G-CSF alone 3 0.5% 1 0.6%     
 HMA 8 1.3% 8 4.6%     
 HY 1 0.2% 2 1.2%     
 LEN 7 1.1% 15 8.6%     
 None 408 64.5% 77 44.0%     
VariableRelative platelet drop
≤25% (n = 632)>25% (n = 175)PMultivariate
n or median% or IQRn or median% or IQROR95% CIP
Sex     .4    
 Male 394 62.3% 103 58.9%     
 Female 238 37.7% 72 41.1%     
Age, y 73 67-79 73 66-79 .5    
WHO classification at diagnosis     .015    
 RA 113 17.9% 28 16.0%  1   
 RARS 122 19.3% 17 9.7%  0.7 0.3-1.3 .2 
 RCMD 230 36.4% 79 45.1%  1.3 0.8-2.1 .4 
 RCMD-RS 39 6.1% 12 6.9%  1.2 0.5-2.5 .7 
 5q− syndrome 34 5.4% 15 8.6%  1.0 0.4-.26 .9 
 RAEB-1 74 11.7% 20 11.4%  0.7 0.4-1.5 .4 
 RAEB-2 0 0.0% 1 0.6%     
 MDS-U 20 3.2% 3 1.7%  0.6 0.2-2.4 .45 
IPSS at inclusion     <10−4    
 Low 332 55.5% 61 36.7%     
 Intermediate-1 266 44.5% 105 63.3%     
BM blasts, %     .1    
 ≤2 362 60.7% 85 51.8%     
 >2 to <5 162 27.2% 51 31.1%     
 5-10 69 11.6% 28 17.1%     
 >10 3 0.5% 0 0.0%     
Peripheral blasts, %     .4    
 <1 477 75.5% 127 72.6%     
 ≥1 155 24.5% 48 27.4%     
No. of cytopenias     <10−4    
 0 132 20.9% 19 10.9%  1   
 1 332 52.5% 84 48.0%  1.3 0.7-2.4 .3 
 2 126 19.9% 46 26.2%  1.7 0.9-3.2 .1 
 3 42 6.7% 26 14.9%  2.4 1.1-5.2 .03 
IPSS-R cytogenetic risk     .5    
 Very good 64 11.2% 20 12.5%     
 Good 431 75.6% 112 70.0%     
 Intermediate 65 11.4% 24 15.0%     
 Poor/very poor 10 1.8% 4 2.5%     
IPSS-R at inclusion     .024    
 Very low 151 27.8% 29 19.7%     
 Low 238 43.7% 59 40.1%     
 Intermediate 118 21.7% 49 33.4%     
 High 32 5.9% 10 6.8%     
 Very high 5 0.9% 0 0%     
Hb level, g/dL 10.2 9.3-11.4 9.5 8.5-10.7 <10−4 0.9 0.8-1.1 .2 
RBC-TD at inclusion     <10−4   .02 
 No 499 79.0% 102 58.3%  1   
 Yes 133 21.0% 73 41.7%  1.7 1.1-2.6  
Platelets, ×109/L 184 108-277 155 89-261 .6    
Neutrophils, ×109/L 2.4 1.5-3.9 2.1 1.2-3.8 .8    
Treatment before landmark     <10−4    
 ESA with or without G-CSF 205 32.4% 72 41.1%     
 G-CSF alone 3 0.5% 1 0.6%     
 HMA 8 1.3% 8 4.6%     
 HY 1 0.2% 2 1.2%     
 LEN 7 1.1% 15 8.6%     
 None 408 64.5% 77 44.0%     
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal